Recent Updates — RGBPP

Regen BioPharma entered into a settlement agreement with Trillium Partners, LP to resolve a $398,740 claim. The company will issue Common or Series A Preferred Stock to the plaintiff, where the remittance amount equals 65% of the net proceeds from the sale of those shares. Additionally, the company appointed Simon & Edward LLP as its new independent registered public accounting firm, replacing BCRG Group following S&E's acquisition of BCRG's attest service business. The company also filed a Certificate of Designation to authorize 1,000 shares of Series N Preferred Stock, which carries significant super-voting rights. Regen BioPharma is a biotechnology company focused on developing regenerative medicines.